News
Kamari Pharma Announces Presentations at the 82nd Annual Meeting of the Society for Investigative Dermatology and the International Pachyonychia Congenita Consortium Symposium
READ MORE >
KM-001, a novel TRPV3 inhibitor, demonstrates safety and preliminary efficacy in Phase 1b clinical study for the treatment of palmoplantar keratoderma
READ MORE >
Novel TRPV3 inhibitors developed for the treatment of palmoplantar keratodermas, demonstrate safety and efficacy in preclinical models
READ MORE >
Kamari Pharma Announces Abstracts Accepted for Presentation at the 81st Annual Meeting of the Society for Investigative Dermatology
READ MORE >
Kamari Pharma Appoints Dr. John Doux to its Board of Directors
READ MORE >
Lichen Simplex Chronicus Itch: An Update
READ MORE >
TRPV3 antagonist treatment reduces pro-inflammatory pathways in Olmsted syndrome keratinocytes
READ MORE >
Kamari Pharma Raises $8 Million from the Sino-Israeli GIBF2 Fund
READ MORE >